Cure My Disease

Don't miss your cure!

 Log in / Sign up

One shot to soothe a torn knee?

NCT ID NCT07539194

Symptom relief Sponsor: Innate srl Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a single injection of hyaluronic acid (Promovia Hydro Balance) for people with a degenerative meniscus tear in the knee. The goal is to see if it improves joint function and reduces pain over 6 months. The trial will enroll 25 adults aged 35 to 75.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \- Age between 35 and 75 years at the time of administration. * Presence of a symptomatic degenerative meniscus tear, not related to acute trauma, documented by MRI. * Positive meniscal tests. * Pain intensity NRS ≥ 4. * Willingness to participate in physical therapy or light exercise. * Informed consent received, understood, and signed by the patient for active participation in the study and for the processing of personal data. * Ability of the patient to understand the study conditions and to participate for the entire duration of the study. Exclusion Criteria: * \- Patients with traumatic meniscus tears. * Patients with a meniscal tear requiring surgical treatment (FLAP tear, radial tear, RAMP tear). * Patients with severe knee osteoarthritis. * Patients with axial deviation greater than 10°. * Patients who have undergone meniscal or ligament surgery in the previous 12 months. * Patients with rheumatic diseases or chondrocalcinosis. * Patients with signs of possible infection in the affected joint or a skin disease involving the knee (e.g., dermatitis, psoriasis). * Patients with diabetes. * Patients with coagulopathies, platelet aggregation disorders, or those receiving oral anticoagulants or antiplatelet drugs. * Patients receiving intra-articular corticosteroids or hyaluronic acid in the previous 12 months. * Pregnant or breastfeeding patients.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Meniscus tears are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Meniscus tears

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO

    RECRUITING

    Milan, MI, Italy